COVID-19 vaccine maker Novavax has announced that it will lay off a quarter of its employees as the company faces “substantial challenges” this year amid the easing of the pandemic. Novavax is focusing on “significantly reducing” its expenses while maintaining critical capabilities that are necessary to execute the company’s operating plans, the firm said in…
Vaccine Maker Announces 25 Percent Layoffs as Pandemic Worries Subside
May 9, 2023
admin
Business & MarketsBusinesses in COVID-19CompaniesCOVID-19 alert systemeconomyNovavaxstaff layoffsUSUS News
0 Comment
Novavax Raises Doubts About Ability to Remain in Business, Shares Fall
NEW YORK—COVID-19 vaccine maker Novavax Inc. on Tuesday raised doubts about its ability to remain in business and announced plans to slash spending as it works to prepare for a fall vaccination campaign, and its shares plunged more than 25 percent. The company said there is significant uncertainty around its 2023 revenue, funding from the…
Novavax COVID-19 Vaccine Associated With Heart Inflammation: Study
A higher than expected number of heart inflammation cases have occurred in people who received Novavax’s COVID-19 vaccine, researchers reported in a new study. Sixty-one cases of myocarditis, pericarditis, or both following a Novavax vaccination were reported in the World Health Organization’s vaccine safety database through Aug. 23, 2022, Spanish researchers found. Using pre-pandemic rates of…
Novavax to Sell US Government 1.5 Million More Doses of COVID-19 Vaccine
Novavax has secured a vaccine deal to provide the U.S. government with 1.5 million doses of its COVID-19 vaccine, a latecomer to a market where the biggest buyers have stopped buying. The Maryland-based biotech company reported on Monday that it has agreed with the U.S. government to modify an existing contract, but did not disclose…
Senators Call for Release of COVID-19 Vaccine Agreements
November 21, 2022
admin
Alex AnticAstrazenecaAustraliaCCP Virusgain of function researchGerard RennickInternationalMatt CanavanModernaNovavaxPfizerRalph BabetVaccines & SafetyWorld
0 Comment
Four Australian senators have lodged an order for the release of contracts between the federal government and pharmaceutical companies for the production of COVID-19 vaccines. The senators will lodge the motion on Nov. 29, 2022, for the current Labor health minister to release agreements with Pfizer, AstraZeneca, Moderna, and Novavax, including details on vaccine efficacy,…
Pentagon is ‘Misleading’ Service Members by Promoting Novavax as ‘Ethical’ Vaccine Option, Attorney Alleges
An Air Force veteran and attorney is calling into question the Pentagon and Air Force’s promotion of Novavax as a vaccine that doesn’t have links to fetal-derived cell lines, saying that this is not the case. With nearly 20 years of military service, Lt. Col. Davis Younts currently serves as an Air Force Reserve Judge…
CDC Recommends Use of Novavax’s COVID-19 Shot for Adolescents
The Centers for Disease Control and Prevention (CDC) on Monday signed off on the use of Novavax Inc.’s COVID-19 vaccine for adolescents aged 12 through 17. The recommendation follows the Food and Drug Administration’s (FDA) authorization for the vaccine for the age group last week. The protein-based vaccine received emergency use authorization in July for…
Novavax Seeks FDA Authorization for Emergency Use of COVID-19 Vaccine Booster
Novavax is seeking emergency authorization of its COVID-19 booster shot in adults aged 18 and older from U.S. regulators, the company announced on Monday. In a press release, the biotechnology company based in Maryland said it has submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its protein-based booster shot. If authorized, the…
Novavax Sinks After Halving Sales Forecast on Low Vaccine Demand, Supply Glut
Novavax Inc. on Monday halved its full-year revenue forecast as it does not expect further sales of its COVID-19 shot this year in the United States in the face of a global supply glut and soft demand, sending its shares down 33 percent. Novavax said it now expects 2022 total revenue in the range of…
Novavax COVID-19 Vaccine Can Cause Heart Inflammation: European Regulator
The COVID-19 vaccine made by U.S.-based Novavax can lead to the same types of heart inflammation that have occurred after vaccination with the Pfizer and Moderna shots, Europe’s drug regulator said on Aug. 3. The European Medicines Agency said the vaccine, known as Nuvaxovid, should have myocarditis and pericarditis listed as side effects in the product…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`